Abstract
Heparin has been used as an anticoagulant for decades. Recently, attention has been drawn to the nonanticoagulant activities of heparin. Experimentally and clinically those non-anticoagulant properties of heparin inhibit inflammation and metastatic spread of tumor cells. On the molecular level, heparin inhibits the function, expression and/or synthesis of adhesion molecules, cytokines, angiogenic factors and complement. However, despite a similar anticoagulant activity, those non-anticoagulant effects of heparin differ greatly among the different heparin preparations. The same holds true for the most common adverse events of heparin treatment. The incidence of immune mediated heparin-induced thrombocytopenia and cutaneous hypersensitivity responses is greatly, but not exclusively, influenced by the heparin preparation used. As the structure-function relationship of the anti-inflammatory and anti-metastatic effects of heparins are understood in more detail, and as the risk profile of different heparin preparations regarding the induction of adverse events have been identified, we propose to use the different heparin preparations according to the individual needs of each patient.
Keywords: Inflammation, metastasis, heparin, glycosaminoglycans, lymphocyte homing, chemokines, angiogenesis, complement, adverse events
Current Drug Discovery Technologies
Title: Therapeutic Use of Heparin beyond Anticoagulation
Volume: 6 Issue: 4
Author(s): Ralf J. Ludwig
Affiliation:
Keywords: Inflammation, metastasis, heparin, glycosaminoglycans, lymphocyte homing, chemokines, angiogenesis, complement, adverse events
Abstract: Heparin has been used as an anticoagulant for decades. Recently, attention has been drawn to the nonanticoagulant activities of heparin. Experimentally and clinically those non-anticoagulant properties of heparin inhibit inflammation and metastatic spread of tumor cells. On the molecular level, heparin inhibits the function, expression and/or synthesis of adhesion molecules, cytokines, angiogenic factors and complement. However, despite a similar anticoagulant activity, those non-anticoagulant effects of heparin differ greatly among the different heparin preparations. The same holds true for the most common adverse events of heparin treatment. The incidence of immune mediated heparin-induced thrombocytopenia and cutaneous hypersensitivity responses is greatly, but not exclusively, influenced by the heparin preparation used. As the structure-function relationship of the anti-inflammatory and anti-metastatic effects of heparins are understood in more detail, and as the risk profile of different heparin preparations regarding the induction of adverse events have been identified, we propose to use the different heparin preparations according to the individual needs of each patient.
Export Options
About this article
Cite this article as:
Ludwig J. Ralf, Therapeutic Use of Heparin beyond Anticoagulation, Current Drug Discovery Technologies 2009; 6 (4) . https://dx.doi.org/10.2174/157016309789869001
DOI https://dx.doi.org/10.2174/157016309789869001 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of An Experimental Model of Atherosclerosis: apoE-knockout Mice in Developing New Drugs against Atherogenesis
Current Pharmaceutical Biotechnology Functional Characteristic of Snake Venom Disintegrins: Potential Therapeutic Implication
Current Pharmaceutical Design Oncolytic Viruses: The Best is Yet to Come
Current Cancer Drug Targets Gut Microbiome and Insomnia: A Mini-Review
New Emirates Medical Journal Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study
Current Medicinal Chemistry - Anti-Cancer Agents Castration Resistant Prostate Cancer: From Emerging Molecular Pathways to Targeted Therapeutic Approaches
Clinical Cancer Drugs Piroxicam-β-Cyclodextrin: A GI Safer Piroxicam
Current Medicinal Chemistry Analogs of Cinnamic Acid Benzyl Amide As Nonclassical Inhibitors of Activated JAK2 Kinase
Current Cancer Drug Targets Tuberoinfundibular Peptide of 39 Attenuates Chronic Unpredictable Mild Stress Induced HPA Axis Dysregulation, Inflammation and Oxidative Damage in Depressive Rats
Current Bioactive Compounds Cell Therapy for Stroke: Emphasis on Optimizing Safety and Efficacy Profile of Endothelial Progenitor Cells
Current Pharmaceutical Design Thiazole Compounds as Antiviral Agents: An Update
Medicinal Chemistry The Infectious Etiology of Alzheimer’s Disease
Current Neuropharmacology The Role of Oxidative Stress and Anti-Oxidant Treatment in Platinum- Induced Peripheral Neurotoxicity
Current Cancer Drug Targets Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Synthesis, Computational Analysis, Antimicrobial, Antioxidant, Trypan Blue Exclusion Assay, β-hematin Assay and Anti-inflammatory Studies of some Hydrazones (Part-I)
Current Computer-Aided Drug Design Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design Editorial: Exploring Lipid-related Treatment Options for the Treatment of NASH
Current Vascular Pharmacology A Novel Rosuvastatin Calcium Cow Ghee Fraction Biform Complex: Formulation Characterization and Evaluation
Drug Delivery Letters Local Gene Delivery for Cancer Therapy
Current Gene Therapy Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design